The ASCENT-04/KEYNOTE-D19 study is a global, open-label, randomized phase III study evaluating the efficacy and safety of ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

If the money lapses this year, 5 million are expected to lose coverage and others would face premium hikes in 2026.

Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report ...

As a physician and researcher, I’m deeply concerned about proposed cuts to Medicaid — as the burden will land on the patients I serve. Equitable access to healthcare is essential to quality cancer ...

A potential cure for a rare type of blood cancer is currently being used to treat 150 patients at various healthcare centers ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...

In this Australian cohort of adults, individuals diagnosed with cancer experienced greater declines in physical functioning ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Q1 2025 Earnings Call Transcript May 27, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $1.39, expectations ...